DERMATOLOGICA SINICA 33 (2015) 166-169

Contents lists available at ScienceDirect

Dermatologica Sinica

journal homepage: http://www.derm-sinica.com

CASE REPORT Concomitant chronic lymphocytic leukemia and Merkel cell carcinoma

Darko Antic ^{1, 2, *}, Jelena Jelicic ¹, Vojin Vukovic ¹, Gordana Pupic ³, Zorka Milovanovic ³, Biljana Mihaljevic ^{1, 2}

¹ Clinic for Hematology, Clinical Center Serbia, Belgrade, Serbia

² Medical Faculty, University of Belgrade, Belgrade, Serbia

³ Department of Pathology, Institute of Oncology and Radiology of Serbia, Belgrade, Serbia

ARTICLE INFO

Article history: Received: Sep 23, 2014 Revised: Nov 11, 2014 Accepted: Dec 15, 2014

Keywords: chronic lymphocytic leukemia Merkel cell carcinoma

ABSTRACT

We present the case of a 69-year-old Caucasian man with a 5-year history of untreated chronic lymphocytic leukemia who presented with Merkel cell carcinoma on the right gluteal region. Six months after surgical treatment of Merkel cell carcinoma, we detected massive lymphadenopathy in the right retroperitoneum descending to the inguinum. A lymph node biopsy confirmed Merkel cell carcinoma relapse, and the patient was unsuccessfully treated with radiotherapy. As patients with chronic lymphocytic leukemia have a risk for developing a secondary malignancy, skin lesions need to be carefully examined and new lymphadenopathy must be pathohistologically evaluated.

Copyright © 2015, Taiwanese Dermatological Association. Published by Elsevier Taiwan LLC. All rights reserved.

Introduction

Chronic lymphocytic leukemia (CLL) is a B lymphocyte-derived neoplasia and the most common adult leukemia, with an incidence rate of three to five cases per 100,000.¹ Usually, CLL has a protracted course, but sometimes it is complicated by the occurrence of secondary malignancies.² Merkel cell carcinoma (MCC) is a rare, highly aggressive, primary cutaneous neuroendocrine malignant tumor, which occurs with an estimated incidence rate of 0.18–0.41 cases per 100,000 persons and has a high mortality rate of 33% at 3 years following diagnosis.^{3,4} Both malignancies tend to occur in the elderly population, with a median age at diagnosis of 70 years for MCC and 72 years for CLL.^{5,6} MCC frequently occurs in cancer survivors as well as in association with hematologic malignancies, particularly B lymphoproliferative disorders.⁵ Indeed, there is growing evidence that patients with CLL have a high risk for developing MCC as a secondary malignancy.^{2,5,7–11}



Here, we present a case of a patient, previously diagnosed with both CLL and MCC, presenting with mass lymphadenopathy.

Case Report

A 69-year-old Caucasian man previously diagnosed with CLL was referred to our clinic in April 2012 for a routine follow-up examination. At that time, he had CLL for 5 years (Rai 0) and did not require any specific or supporting therapy. Physical examination revealed an oval, red, firm, verrucous lesion $(3 \times 4 \text{ cm}^2)$ in the right gluteal region, which the patient had noticed 4 months earlier and which was growing rapidly. Other than this lesion, his physical examination was unremarkable. With the exception of leukocytosis $(22.6 \times 10^9/\text{L})$ and mild creatinine elevation (139 µmol/L) due to previously diagnosed chronic renal failure, his laboratory analyses were normal. The skin tumor was completely excised (margins were tumor free), and pathohistological analysis confirmed MCC. The tumor was located in the dermis and had infiltrated the subcutaneous tissue. The tumor cells were monomorphic, with a





CrossMark

Conflicts of interest: The authors declare that they have no financial or nonfinancial conflicts of interest related to the subject matter or materials discussed in this article.

^{*} Corresponding author. Clinic for Hematology, Clinical Center Serbia, Koste Todorovica 2, 11 000 Belgrade, Serbia.

E-mail address: darko.antic1510976@gmail.com (D. Antic).

minimal amount of cytoplasm and uniform nuclei. The predominant histological pattern was diffuse (Figure 1A). Immunohistochemical analysis revealed that many of the tumor cells were positive for synaptophysin (clone SP11; Thermo Lab Vision, Fremont, California, USA) (Figure 1B), CK20 (clone Ks20.8; Thermo Lab Vision) (Figure 1C), NSE (clone E27; Dako, Glostrup, Denmark) (Figure 1D), chromogranin A (clone LK2H10: Thermo Lab Vision), and AE1/AE3 (clone AE1/AE3: Thermo Lab Vision): there was focal positivity for CD57 (clone NK1; Thermo Lab Vision) and EMA (focal) (clone E29; Thermo Lab Vision). None of the tumor cells were positive for LCA (clone PD7/26+2B11; Thermo Lab Vision), CD10 (clone 56C6; Thermo Lab Vision), CD30 (clone Ber-H2; Thermo Lab Vision), CD43 (clone DF-T1; Thermo Lab Vision), CD20 (clone L26; Thermo Lab Vision), CD3 (clone SP7; Thermo Lab Vision), ALK (clone SP8; Thermo Lab Vision), vimentin (clone V9; Thermo Lab Vision), aktin (clone 1A4; Thermo Lab Vision), desmin (clone D33; Thermo Lab Vision), S100 (polyclonal; Thermo Lab Vision), CD34 (clone QBEnd10; Thermo Lab Vision), and PSA (clone 35H9; Novocastra, Nussloch, Germany). The proliferative fraction, as detected by Ki-67 staining (clone SP6; Thermo Lab Vision), was greater than 50% in some high power field (HPF).

After surgery, adjuvant therapy was not advised. Six months later, the patient presented with painless right inguinal lymphadenopathy and right leg edema. Computed tomography of abdomen revealed a large ($19 \times 2.5 \times 10.8 \text{ cm}^3$) lobulated mass, which enveloped the iliac blood vessels like a muff and descended through the right inguinal region (Figure 2). His blood count was stable, and there was no organomegaly. However, a clinical dilemma with regard to the differential diagnosis of lymphade-nopathy arose (CLL transformation vs. MCC metastasis). Therefore, pathohistological analysis was required, and MCC infiltration of the lymph nodes was confirmed. As the tumor was inoperable, local radiotherapy (total dose 36 Gy) was performed. However, a control computed tomography scan showed local disease progression with bladder infiltration. The patient was then treated with only palliative symptomatic therapy.

Discussion

Patients with CLL have a risk of developing a second neoplasm, particularly skin or lung cancer.^{2,12} The appearance of any suspicious extranodal lesions and rapid lymph node enlargement require urgent histological confirmation in order to differentiate between disease transformation (Richter syndrome) and secondary malignancy. MCC is a relatively newly identified malignancy that has occurred with increasing prevalence in the past decade.^{3,13} One of the hallmarks of MCC is its tendency to occur in association with other neoplasms, particularly B lymphoproliferative disorders.^{4,5,7,9,14} A great number of case reports, as well as some larger population studies, unequivocally showed that patients with CLL were at increased risk for developing MCC, and vice versa.^{5,8,9,14} Despite extensive research, knowledge of the etiopathogenesis of MCC is still limited. It has been postulated that exposure to ultraviolet light and immunosuppression are risk factors for development of MCC.³ Indeed, patients with chronic immunosuppression are approximately 15 times more likely to develop MCC than agematched controls.¹⁵ On the other hand, immunosuppression is one of the well-known features of CLL. Although CLL is primarily a B lymphocyte-derived neoplasia, it alters both cellular and humoral immunity, including B- and T-lymphocytic, granulocytic, and monocytic functions; natural killer cell and complement activity; as well as cytokine balance.¹⁶ The recent discovery of the association of Merkel cell polyomavirus (MCV) with MCC was a major contribution to an improved understanding of this rare neoplasm's



Figure 1 Pathohistological and immunohistochemical features. (A) Low-power view showed tumor growth in the dermis and infiltration of the subcutaneous tissue. The tumor cells were monomorphic, with a minimal amount of cytoplasm and uniform nuclei. The predominant histological pattern was diffuse (original magnification, $100 \times$). (B) Many tumor cells showed strong immunoreactivity for synaptophysin (original magnification, $100 \times$). (C) Strong staining for CK20 with infiltration of adipose tissue (original magnification, $200 \times$). (D) Many tumor cells showed strong immunoreactivity for NSE (original magnification, $100 \times$).

Download English Version:

https://daneshyari.com/en/article/3196340

Download Persian Version:

https://daneshyari.com/article/3196340

Daneshyari.com